FluoSphera raises CHF 1.15M to scale human-based preclinical platform
13.01.2026
Geneva-based biotech startup FluoSphera has raised CHF 1.15 million to scale its human-based preclinical testing platform. Already working with international pharmaceutical companies and research laboratories, the company aims to expand commercial collaborations and further develop its technology to improve how new drug candidates are evaluated before entering clinical trials.
 |
 |
Drug development remains costly and inefficient, with over 90% of candidates failing in clinical trials due largely to the limits of traditional preclinical models. Conventional cell cultures and animal testing often fail to predict how compounds behave in the human body, leading to late-stage failures and high R&D costs.
Venture Kick alumni FluoSphera, also ranked among the Top100 Swiss Startups, addresses this gap with a multiplexed in vitro platform that combines up to six or seven human tissue models in a single well. Using proprietary fluorescent coding, the technology enables simultaneous assessment of efficacy and safety by capturing organ-level interactions in one experiment. The platform is already used by biotech and pharmaceutical companies, particularly for antibody-drug conjugate testing, and is compatible with high-throughput screening workflows.
With the new funding, FluoSphera will scale commercial collaborations, expand its business development team, and advance its AI-driven image analysis capabilities. Growth efforts will focus on the US and EU, with initial expansion into Asia underway.
Fluosphera co-founders Gregory Segala and Clelia Bourgoint
Venture Kick alumni FluoSphera, also ranked among the Top100 Swiss Startups, addresses this gap with a multiplexed in vitro platform that combines up to six or seven human tissue models in a single well. Using proprietary fluorescent coding, the technology enables simultaneous assessment of efficacy and safety by capturing organ-level interactions in one experiment. The platform is already used by biotech and pharmaceutical companies, particularly for antibody-drug conjugate testing, and is compatible with high-throughput screening workflows.
With the new funding, FluoSphera will scale commercial collaborations, expand its business development team, and advance its AI-driven image analysis capabilities. Growth efforts will focus on the US and EU, with initial expansion into Asia underway.
Fluosphera co-founders Gregory Segala and Clelia Bourgoint